Durvalumab activity in previously treated patients who stopped durvalumab without disease progression.

ABSTRACT:

Background

Limited data exist on potential clinical benefit with anti-programmed cell death ligand-1 (PD-L1) retreatment in patients who stop initial therapy for reasons other than disease progression or toxicity and develop disease progression while off treatment.

Patients and methods

NCT01693562 was a phase I/II study evaluating durvalumab monotherapy in advanced solid tumors. Patients benefiting from treatment were taken off durvalumab at 1 year per protocol and prospectively followed. At disease progression, they were eligible for durvalumab retreatment. Outcomes evaluated during retreatment included best overall response (BOR2), duration of response (DoR2), disease control rate (DCR2), and progression-free survival (PFS2).

Results

Of 980 patients enrolled and tre

SUBMITTER: Sheth S 

PROVIDER: S-EPMC7451272 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature